Free Trial
NASDAQ:SRRK

Scholar Rock Q2 2023 Earnings Report

Scholar Rock logo
$28.86 -1.61 (-5.28%)
Closing price 04:00 PM Eastern
Extended Trading
$29.92 +1.06 (+3.68%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scholar Rock EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.53
Beat/Miss
Beat by +$0.06
One Year Ago EPS
-$1.06

Scholar Rock Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scholar Rock Announcement Details

Quarter
Q2 2023
Time
After Market Closes
Conference Call Date
Wednesday, August 9, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Scholar Rock's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 8:15 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Scholar Rock Earnings Headlines

Wedbush Forecasts Scholar Rock's Q2 Earnings (NASDAQ:SRRK)
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.
What is Wedbush's Forecast for Scholar Rock FY2029 Earnings?
See More Scholar Rock Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scholar Rock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scholar Rock and other key companies, straight to your email.

About Scholar Rock

Scholar Rock (NASDAQ:SRRK), a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

View Scholar Rock Profile

More Earnings Resources from MarketBeat